ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022
Blood-Based Biomarker Panel for Personalized Lung Cancer Risk Assessment.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 3 syntheses or guidelines pooled it, 94 citations in OpenAlex.
- Risk prediction for lung cancer screening: a systematic review and meta-regression.European respiratory review : an official journal of the European Respiratory Society · 2026Pooled it
- Pooled it
- Time to Benefit for Lung Cancer Screening: A Systematic Review and Survival Meta-Analysis.American journal of preventive medicine · 2025Pooled it
- Plasma proteomic profiles associated with low-dose computed tomography findings and incident lung cancer: a prospective pilot study.Translational lung cancer research · 2026Article
- Bias in Meta-Analytic Modeling of Surrogate Endpoints in Cancer Screening Trials.Statistics in medicine · 2026Article
- Performance validation and clinical concordance of a novel fully automated immunoassay system for five tumor markers: A comparative study with an international reference platform.Practical laboratory medicine · 2026Article
- Blood-based DNA methylation marker model for short-term and long-term lung cancer risk prediction.BMC medicine · 2026Article
- Artificial Intelligence in Lung Cancer: From Early Detection to Personalized Therapy.Current oncology reports · 2026Review
- Integration of blood protein-metabolic profiles via machine learning to enable the accurate early detection of non-small cell lung cancer.Respiratory research · 2026Article
- Next-generation proteomics improves lung cancer risk prediction.Molecular oncology · 2026Article
- Machine learning-based proteogenomic data modeling identifies circulating plasma biomarkers for early detection of lung cancer.Communications medicine · 2026Article
- Lung cancer in never-smoking females: epidemiology, risk factors and screening.Frontiers in public health · 2026Review
- Dynamic screening initiation using 16 plasma protein biomarkers with polygenic risk and PLCOm2012: a precision prevention framework for lung cancer.Journal of translational medicine · 2025Article
- SMAGS-LASSO: A Novel Feature Selection Method for Sensitivity Maximization in Early Cancer Detection.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Validation of a blood test for multi-cancer risk stratification in a lung cancer screening cohort.medRxiv : the preprint server for health sciences · 2025Article
- Updates in Lung Cancer Screening: A Decade of Evidence.Seminars in respiratory and critical care medicine · 2025Review
- T-cell Receptor Profiling of Blood to Detect Lung Cancer.Cancer immunology research · 2025Article
- Biomarkers for the diagnosis of indeterminate pulmonary nodules: are we there yet?Journal of thoracic disease · 2025Review
- External Validation of Plasma Glycosaminoglycans as Biomarkers to Improve Lung Cancer Risk Stratification.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Plasma exosomal tsRNA may be used as a marker for differential diagnosis of benign and malignant pulmonary nodules.Journal of translational medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 2 countries.
Funding
Abstract
purposeTo investigate whether a panel of circulating protein biomarkers would improve risk assessment for lung cancer screening in combination with a risk model on the basis of participant characteristics.
methodsA blinded validation study was performed using prostate lung colorectal ovarian (PLCO) Cancer Screening Trial data and biospecimens to evaluate the performance of a four-marker protein panel (4MP) consisting of the precursor form of surfactant protein B, cancer antigen 125, carcinoembryonic antigen, and cytokeratin-19 fragment in combination with a lung cancer risk prediction model (PLCO
resultsThe 4MP alone yielded an area under the receiver operating characteristic curve of 0.79 (95% CI, 0.77 to 0.82) for case sera collected within 1-year preceding diagnosis and 0.74 (95% CI, 0.72 to 0.76) among the entire specimen set. The combined 4MP + PLCO
conclusionA blood-based biomarker panel in combination with PLCO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.